Related Experiment Video
Updated: Aug 15, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Treatment of recurred HCV infection after liver transplantation]
Takafumi Ichida1, Hiroki Mori, Satoshi Abe
1Department of Gastroenterology, Juntendo University, School of Medicine, Shizuoka Hospital.
Abstract:
Prognosis of recurred HCV recipient after both deceased and live liver transplantation is quite worse in foreign countries, recently. The reason of this poor prognosis is believed as immune-suppressant, steroid bolus, aged donor and liver donor in USA and Europe. However, in Japan, survival ration of HCV recipients is 5% reduction than mean survival of live donor liver transplantation. In addition, post transplant treatment of recurred HCV recipient is not good result in out of Japan, because of high rate of withdraw or drop out with peg interferon and ribavirin. On the contrary, some of Japanese investigator reported with 40-50% SVR with same drug management. It is still controversy whether HCV recipients are poor prognosis after transplantation and treatment resistance.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Kidney Transplant II: Surgical Procedure